Establishment and characterization of two different types of new human endometrial adenocarcinoma cell lines (HEC-251 and HEC-265)

Objective: Endometrial carcinomas are grouped into two types of carcinogenic entities. These two different types of cell lines designated as HEC-251 and HEC-265 were established from human endometrial adenocarcinoma. We report their characteristics.

Materials: HEC-251 was derived from moderately differentiated endometrioid adenocarcinoma and HEC-265 from well-differentiated adenocarcinoma.

Results: These cell lines grow well and serial passages can be successively carried out more than 100 times. The monolayer cultured cells reveal neoplastic and pleomorphic features, and grow in multilayers. HEC-251 cells are immuno-cytochemically positive for p53 and HEC-265 cells for PgR. Both cell lines are transplantable to nude mice and reflect the original histopathologic characteristics.

Conclusion: The cell lines HEC-251 and HEC-265 will contribute to clarifying the characteristics of two different types of human endometrial carcinomas.

Endometrial adenocarcinoma; Uterine neoplasm; Cell line; p53; PgR

[1] Kuranoto H., Hamano M., Imai M., Fujisawa T., Kamala Y., Arm T., Kawaguchi M.: "HEC-1 Cells: Establishment of in vitro experimental system in endometrial carcinoma". In: "Cell and Molecular Biology of Endometrial Carcinoma". Kuramoto H. and Nishida M. (ed.), Tokyo, Springer-Verlag, 2003, 3.

[2] Jobo T., Tateoka K., Kuramoto H.: "Study on the long term followup of endometrial hyperplasia". Int. J. Clin. Oneal., 1996, 1 (3), 163.

[3] Ohkawara S., Jobo T., Sato R., Kuramoto H.: "Comparison of endometrial carcinoma coexisting with and without endometrial hyperplasia". Eur. J. Gynaecol. Oneal., 2000, 21 (6), 573.

[4] Fujimoto J., Hirose R., Sakaguchi H., Tamaya T.: "Estrogen dependency in uterine endometrial cancers". Oncology, 1998, 55, 53.

[5] Fujisawa T., Watanabe J., Akaboshi M., Ohno E., Kuramoto H "Immunohistochemical study on VEGF expression in endometrial carcinoma - Comparison with p53 expression, angiogenesis and tumor histologic grade". J. Cancer Res. Clin. Oncol., 2001, 127, 668.

[6] Ohotani K., Sakamoto H., Satoh K.: "Molecular pathogenesis of endometrial hyperplasia and Adenocarcinoma". Nihon. Univ. J. Med., 1999, 41, 181.

[7] Inoue M., Okayama A., Fujita M., Enomoto T., Sakata M., Tanizawa O., Ueshima H.: "Clinicopathological characteristics of p53 overexpression in endometrial cancers". Int. J. Cancer, 1994, 58, 14.

[8] Kimura K., Watanabe J., Hata H., Fujisawa T., Kamata Y., Nishimura Y. et al.: "PTEN immunohistochemical expression is suppressed in G 1 endometrial adenocarcinoma of the uterine corpus". J. Cancer Res. Clin. Oncol. (in press, published online, 20 Dec.'03).

[9] Fujiwaki R., Hata K., Iida K., Maede Y., Watanabe Y., Koike M., Miyazaki K.: "Co-expression of vascular endothelial growth factor and thymidin phosphorylase in endometrial cancer". Acta Obstet. Gynecol. Scand., 1999, 78, 728.

[10] Heffner H.M., Freedman A.N., Asirwatham J.E., Lele S.B.: "Prognostic significance of p53, PCNA, and c-erbB-2 in endometrial adenocarcinoma". Eur. J. Gynaecol. Oneal., 1999, 20, 8.

[11] Powell B., Soong R., Grieu F., Knowles S., Hammond I., Iacopetta B.: "p53 protein overexpression is a prognostic indicator of poor survival in stage I endometrial carcinoma". Int. J Oneal., 1999, 14, 175.

[12] Salvesen H.B., lvrsen O.E., Akslen L.A.: "Prognostic significance of angiogenesis and Ki－67, p53, p21 expression: A population-based endometrial carcinoma study". J. Clin. Oneal., 1999, 17, 1382.

[13] Kamata Y., Watanabe J., Hata H., Hamano M., Kuramoto H.: "Quantitative study on the correlation between p53 gene mutation and its expression in endometrial carcinoma cell lines". Eur. J. Gynaecol. Oneal. (in press)

[14] Imai M., Jobo T., Sato R., Kawaguchi M., Kuramoto H.: "Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-Usefulness and limitations". Eur. J. Gynaecol. Oncol., 2001, 22, 217.

[15] Jobo T., Imai M., Kawaguchi M., Kenmochi M., Kuramoto H. "Successful conservative treatment of endometrial carcinoma permitting subsequent pregnancy: Report of two cases". Eur. J. Gynaecol. Oncol., 2000, 21, 119.

[16] Kuramoto H., Tamura S., Notake Y: "Establishment of a cell line of human endometrial adenocarcinoma in vitro". Am. J. Obstet. Gynecol., 1972, 114, 1012.

[17] Kuramoto H., Hamano M., Nishida M. et al.: "Establishment of a cell line of human endometrial carcinoma originated from ascitic fluid". Act. Obstet. Gynaecol. Jpn., 1976, 28, 1405.

[18] Kuramoto H., Hamano M.: "Establishment and characterization of the cell-line of a human endometrial adenoacanthona". Eur. J. Cancer, 1977, 13, 253.

[19] Morisawa T.: "The results of primary culture of endometrial adenocarcinoma and characterization of its established cell lines". J. Jpn. Soc. Clin. Cytol., 1987, 26, 433.

[20] Kuramoto H., Nishida M., Morisawa T. et al.: "Establishment and charactarization of human endometrial cancer cell lines". Ann. N. Y. Acad. Sci., 1991, 622, 402.